TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $45
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
TD Cowen analyst Steve Scala maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $42 to $45.
TD Cowen analyst Steve Scala maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $42 to $45.